Related Experiment Videos
[Chemotherapy for recurrent breast carcinoma].
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1985
Summary
Combination chemotherapy, including regimens like CMF and AC, shows a 30-50% response rate for advanced breast cancer. Treatment choice depends on recurrence factors, with new drug testing crucial.
Area of Science:
- Oncology
- Pharmacology
Context:
- Advanced breast cancer treatment often involves single-agent chemotherapy.
- Recurrent breast cancer presents significant challenges in selecting effective treatment regimens.
Purpose:
- To review the efficacy of combination chemotherapy regimens for progressive recurrent breast cancer.
- To discuss challenges and considerations in selecting chemotherapy and hormone therapy combinations.
Summary:
- Several anticancer agents like 5-FU, Cyclophosphamide (CPA), Methotrexate (MTX), Adriamycin (ADM), and Vincristine (VCR) are effective individually against recurrent breast cancer.
- Combination regimens such as CMF, CMFVP, and AC demonstrate a 30-50% overall response rate.
- Treatment selection is complex, influenced by recurrence site, prior treatments, and the potential for combining agents not used in primary regimens.
Impact:
- Combination chemotherapy offers improved response rates compared to single-agent therapy for recurrent breast cancer.
- Highlights the need for personalized treatment strategies and ongoing research into novel therapeutic agents.